Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*Sophie Georgin‐Lavialle, Thomas Cluzeau, Valentin Lacombe et al.|British Journal of Dermatology|2021Cited by 414
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter studyMaël Heiblig, Pierre Sujobert|Blood|2022Cited by 201
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registryBenjamin De Valence, Mikaël Ebbo, M. Delaune et al.|Annals of the Rheumatic Diseases|2023Cited by 70